Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPA1 | P27694 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.36 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180133 | 0.83 | RPA1 (0.42) | RPA1CNR2S1PR1PGRALDH1A1 | |
| SCHEMBL3828979 | 0.81 | CNR2 (0.37) | RPA1CNR2CACNA1HS1PR1PGR | |
| SCHEMBL922038 | 0.81 | RPA1 (0.63) | RPA1CNR2S1PR1PGRALDH1A1 | |
| SCHEMBL6654063 | 0.75 | TRPA1 (0.48) | CNR2TRPA1GPR119 | |
| SCHEMBL4631024 | 0.73 | CNR2 (0.43) | RPA1CNR2S1PR1PGRNR4A1 | |
| SCHEMBL3831419 | 0.72 | PGR (0.39) | RPA1CNR2PGRALDH1A1KDM4E | |
| SCHEMBL2988579 | 0.72 | CACNA1H (0.45) | CACNA1HS1PR1TRPA1ALDH1A1 | |
| SCHEMBL2657643 | 0.71 | GRM4 (0.41) | CNR2TRPA1ALDH1A1KDM4EEGLN2 | |
| SCHEMBL13443543 | 0.70 | LIPG (0.43) | CACNA1HS1PR1PGRTRPA1ALDH1A1 | |
| SCHEMBL22835128 | 0.69 | HDAC4 (0.44) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| US-7884126-B2 | serum and glucocorticoid dependent kinase (SGT)and serine/threonine kinase checkpoint kinase (CHK) inhibitors such as 5-(3-Benzoylamino-1H-indazol-5-yl)furan-2-carboxylic acid, used for the treatment of cancer | MERCK PATENT GMBH (DE) | 2011-02-08 | — | — | US | disclosed |
| EP-1981878-B1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20090076091-A1 | INDAZOLE-HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076091-A1 | INDAZOLE-HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076091-A1 | INDAZOLE-HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| WO-2007090493-A1 | INDAZOLE HETEROARYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090494-A1 | AMINO INDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076091-A1 | INDAZOLE-HETEROARYL DERIVATIVES | CHEK2, CHEK1, SGK3 | RPA1 790/4885CNR2 3067/4885CACNA1H 4558/4885 |
| US-20090036508-A1 | AMINO INDAZOLE DERIVATIVES | CHEK1, CHEK2, SGK3 | RPA1 430/4885CNR2 3437/4885CACNA1H 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.